D. Tripathy

Nola Hylton, Carolyn Mies, Olufunmilayo I Olopade, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen Receptor Function and Androgen Receptor–Targeted Therapies in Breast Cancer: A Review

D. Tripathy, N. Ueno, B. Lim, 2017, JAMA oncology.

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

Xifeng Wu, W. Chow, D. Tripathy, 2019, Breast Cancer Research and Treatment.

Adjuvant Trastuzumab: Lessons Learned from Large Trials and Preliminary Results

D. Tripathy, 2006 .

How long should adjuvant tamoxifen be continued?

D. Tripathy, 1994, Oncology.

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

D. Tripathy, 2009 .

Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer

Diane D. Liu, Helen X. Chen, D. Tripathy, 2018, Oncotarget.

Dietary Fat Reduction Improves Relapse-Free Survival in Postmenopausal Women Previously Treated for Early-Stage Breast Cancer: Results from a Phase III Women's Intervention Nutrition Study

D. Tripathy, G. Reddy, 2005 .

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

G. Hortobagyi, L. Pusztai, D. Tripathy, 2021, The New England journal of medicine.

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation

P. Brown, V. Valero, N. Ibrahim, 2017, Journal of Cancer.

Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.

D. Tripathy, J. Body, I. Diel, 2006, European journal of cancer care.

Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.

D. Tripathy, M. Campbell, M. Tagliaferri, 2002, Anticancer research.

First-Line Treatment with Bevacizumab and Paclitaxel Prolongs Progression-Free Survival in Metastatic Breast Cancer

D. Tripathy, P. Tyagi, 2005 .

Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M. D. Anderson Cancer Center Experience

D. Tripathy, 2007 .

Safety of Oral Ibandronate in the Treatment of Bone Metastases from Breast Cancer

D. Tripathy, D. Cameron, D. Tripathy, 2006, Clinical drug investigation.

A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays: Charpin C, Secq V, Giusiano S, et al (Hôpital Nord, Université de la Méditerranée (Aix Marseille II), France; et al) Int J Cancer 124:2124-2134, 2009§

D. Tripathy, 2010 .

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

C. Osborne, C. Benz, D. Tripathy, 1992, Breast Cancer Research and Treatment.

Growth factors and their receptors.

C. Benz, D. Tripathy, Debasish Tripathy, 1994, Hematology/oncology clinics of North America.

Biological Therapy of Breast Cancer

L. Esserman, D. Tripathy, John W. Park, 2012, BioDrugs.

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

D. Berry, L. Esserman, N. Hylton, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)

H. Linden, G. Hortobagyi, D. Tripathy, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Looking ahead to rational combinatorial therapy

D. Tripathy, A. Mittra, 2012 .

HER-2 gene amplification can be acquired as breast cancer progresses.

Tanja Fehm, Sanjay Shete, Leon W M M Terstappen, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Anne M Wallace, Michael Hogarth, Lajos Pusztai, 2016, The New England journal of medicine.

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Jeffrey T. Chang, Jing Wang, Fei Yang, 2019, Cancers.

Activated oncogenes and putative tumor suppressor genes involved in human breast cancers.

C. Benz, D. Tripathy, 1992, Cancer treatment and research.

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment

Carlos L. Arteaga, S. Hanash, D. Tripathy, 2023, Breast Cancer Research.

Molecular markers for breast cancer diagnosis, prognosis and targeted therapy

D. Tripathy, M. Press, J. Lang, 2015, Journal of surgical oncology.

Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.

D. Tripathy, B. Overmoyer, I. Henderson, 2005, Clinical breast cancer.

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

D Tripathy, B. Weber, J. Baselga, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies

D. Tripathy, 2005 .

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.

R. Jagsi, W. Woodward, G. Hortobagyi, 2020, JAMA oncology.

448 Alleviation of bone pain with oral and intravenous ibandronate in women with metastatic breast cancer

D. Tripathy, J. Body, I. Diel, 2003 .

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

M. Ellis, E. Winer, D. Lake, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

D. Berry, L. Esserman, N. Hylton, 2020, JAMA oncology.

Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience

G. Hortobagyi, M. Guindani, W. Murphy, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of 1-year intravenous ibandronate treatment on time to serum creatinine increase in patients with skeletal metastases from breast cancer.

D. Tripathy, J. Body, I. Diel, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complementary and alternative medicine in early-stage breast cancer.

D. Tripathy, M. Tagliaferri, I. Cohen, 2001, Seminars in oncology.

Making a difference in refractory breast cancer

D. Tripathy, 2011 .

Neurocognitive deficits in older patients with cancer.

S. Kesler, V. Valero, D. Tripathy, 2018, Journal of geriatric oncology.

DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes

W. Woodward, H. Kuerer, K. Hunt, 2017, Journal of Cancer.

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

D. Tripathy, E. Thara, 2012 .

Overall survival in older patients with cancer

V. Valero, D. Tripathy, C. Dinney, 2018, BMJ Supportive & Palliative Care.

Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers

Mary W. Yamashita, D. Tripathy, H. Macdonald, 2020, Journal of surgical oncology.

Risk factors for falls in older patients with cancer

V. Valero, D. Tripathy, C. Dinney, 2017, BMJ Supportive & Palliative Care.

Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience

W. Murphy, V. Valero, D. Tripathy, 2018, Supportive Care in Cancer.

Time to begin adjuvant chemotherapy and survival in breast cancer patients: A retrospective observational study using latent class analysis

D. Tripathy, S. Sikaria, 2014 .

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)

D. Berry, L. Esserman, C. Lehman, 2012, Breast Cancer Research and Treatment.

2007 Highlights from: The 29th Annual San Antonio Breast Cancer Symposium San Antonio, TX, December 2006

D. Tripathy, J. O’Shaughnessy, S. Peck, 2007 .

Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

D. Tripathy, C. Bertelsen, Debasish Tripathy, 2012 .

What symptoms are important to patients? Developing a symptom burden measure for women with breast cancer

D. Tripathy, L. Williams, M. Whisenant, 2019, Supportive Care in Cancer.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.

Adjuvant chemotherapy in Older Women with Early-Stage Breast Cancer

D. Tripathy, 2010 .

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative

H. Kuerer, D. Tripathy, B. Arun, 2015, Journal of Cancer.

Expression profiling of circulating tumor cells in metastatic breast cancer

L. Esserman, D. Tripathy, D. Wolf, 2014, Breast Cancer Research and Treatment.

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

N. Ibrahim, D. Booser, D. Tripathy, 2023, Cancer.

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy

D. Tripathy, R. Layman, J. Mouabbi, 2023, JAMA Network Open.

Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.

D. Tripathy, L. Middleton, A. Raghavendra, 2023, European journal of cancer.

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

D. Tripathy, R. Bell, D. Tripathy, 2004, British Journal of Cancer.

Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

L. Esserman, N. Hylton, D. Yee, 2019, Clinical Trials.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

L. Harris, D. Tripathy, S. Shak, 2001, European journal of cancer.

Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer

D. Tripathy, N. Love, R. Carlson, 2005 .

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

L. Esserman, N. Hylton, O. Olopade, 2016, The New England journal of medicine.

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)

D. Berry, L. Esserman, C. Lehman, 2012, Breast Cancer Research and Treatment.

Title: the Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer Statement of Translational Relevance

Parker, D. Berry, E. Petricoin, 2015 .

Oral Oncolytics: Using Remote Technology to Improve Access, Operational Efficiency, and Satisfaction.

D. Tripathy, A. Raghavendra, Abbey Kaler, 2022, Clinical journal of oncology nursing.

A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.

G. Hortobagyi, L. Pusztai, D. Tripathy, 2021, Clinical Cancer Research.

Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer.

Karen R. Sepucha, L. Esserman, D. Tripathy, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.